Mercado global de vacinas contra a gripe – Tendências do setor e previsão para 2029

Análise e dimensão do mercado de vacinas contra a gripe

O foco principal das actividades da UNICEF nos últimos 70 anos tem sido a imunização. Não existe uma organização mais adequada para cuidar de crianças em todo o mundo. Como parceiro técnico do programa de imunização do governo indiano, a UNICEF está empenhada em ajudar o governo a garantir que nenhuma criança sofra de doenças que possam ser prevenidas através da vacinação.

A Data Bridge Market Research analisa que o mercado de vacinas contra a gripe, que foi de 7,5 mil milhões de dólares em 2021, dispararia para 14,83 mil milhões de dólares até 2029, e deverá passar por um CAGR de 8,90% durante o período de previsão de 2022 a 2029. Para além dos insights de mercado, tais como o valor de mercado, a taxa de crescimento, os segmentos de mercado, a cobertura geográfica, os participantes do mercado e o cenário de mercado, o relatório de mercado com curadoria da equipa de investigação de mercado da Data Bridge inclui também análise especializada aprofundada, epidemiologia do paciente, análise de pipeline, análise de preços e quadro regulamentar.

Âmbito e segmentação do mercado de vacinas contra a gripe      

Definição de mercado

As vacinas contra a gripe são referidas como "injeções contra a gripe" ou "vacinações contra a gripe". Com a rápida evolução do vírus da gripe, é criada uma nova vacinação duas vezes por ano. Embora isto mude de ano para ano, a maioria oferece uma protecção modesta a forte contra a gripe. Há poucas evidências entre as pessoas com mais de 65 anos. O ambiente que rodeia uma criança pode ser protegido através da vacinação.

Dinâmica global do mercado de vacinas contra a gripe

Motoristas

• Aumento do volume de doentes que sofrem de gripe

As características dos vírus em circulação, o momento da estação, a forma como a vacina protege contra as doenças e quantas pessoas receberam vacinas, desempenham todos um papel na determinação da gravidade da gripe nos Estados Unidos. A gripe tem diversas consequências. O CDC estima que a gripe tenha resultado em 9 milhões – 41 milhões de doenças, 140.000 – 710.000 hospitalizações e 12.000 – 52.000 mortes anualmente entre 2010 e 2020. Isto impulsionará o crescimento do mercado.

• Aumentar a consciencialização sobre a imunização

Uma das intervenções de saúde mais eficazes e económicas do mundo, a vacinação salva milhões de vidas todos os anos. Em todo o mundo, as vacinas impedem que doenças infeciosas como a hepatite, a difteria, o tétano, a tosse convulsa (coqueluche), o sarampo e a poliomielite matem até 3 milhões de pessoas todos os anos. No entanto, apesar da eficácia demonstrável das vacinas e das dezenas de milhões de vidas que salvaram, estima-se que 400 000 pessoas na região do Pacífico Ocidental morrem desnecessariamente todos os anos devido a doenças que as imunizações poderiam ter evitado. Cerca de 800 000 crianças não são imunizadas todos os anos e mais de 3,2 milhões de crianças residem em áreas com taxas de cobertura vacinal inferiores a 80%. Isto impulsionará o crescimento do mercado.

Oportunidades

• Iniciativas governamentais

De acordo com um inquérito recente realizado nos 190 distritos onde a Missão Indradhanush foi recentemente implementada, a percentagem de crianças que receberam todas as vacinas recomendadas aumentou 18,5% desde as estimativas anteriores à Missão Indradhanush. Para alcançar e manter o objectivo da Índia de 90% de cobertura vacinal total, estão a ser aplicadas lições da Missão Indradhanush para encontrar todas as crianças não convidadas em todo o país.

Restrições/Desafios

• Alto custo

On the other hand, the stringent regulations regarding the implementation and timelines along with high cost of vaccine development will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the flu vaccines market.

This flu vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the flu vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Flu Vaccines Market

The global flu vaccines market is expected to rise as a result of the COVID-19 outbreak. As more people become infected with the COVID-19 virus, demand for the flu vaccines rises. The flu vaccine will not protect against COVID-19, but it will lessen sickness, hospitalisation, and mortality. In 2021, it was announced by the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) that 75,000 COVID-19 patients who received the flu vaccine were less likely to develop sepsis, stroke, and deep vein thrombosis. According to the same source, it was discovered in 2021 that the flu vaccine might provide defence against the COVID-19 virus. Patients with COVID-19 who have received an influenza vaccination had a lower likelihood of being admitted to an intensive care unit.

Recent Development

• In February 2021, A legally binding agreement was reached by GlaxoSmithKline plc and Vir Biotechnology, Inc. to broaden their current partnership to encompass the investigation and creation of fresh treatments for influenza and other respiratory viruses.
• In March 2021, At its current location in Toronto, Canada, Sanofi announced that it will invest more than €600 million in a new vaccine manufacturing facility.
• In November 2020, Seqirus announced that it would build a brand-new, top-notch biotech manufacturing plant in Australia to provide influenza vaccinations to that country and the rest of the world.

Global Flu Vaccines Market Scope

The flu vaccines market is segmented on the basis of influenza type, manufacturing technology, vaccine type, age group, dosage form and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Influenza Type

• Seasonal
• Zoonotic

 Manufacturing Technology

• Egg-Based
• Cell Culture-Based
• Recombinant-Based

Vaccine Type

• Quadrivalent Influenza Vaccines
• Trivalent Influenza Vaccines
• Whole Virus Vaccines
• Split Virus Vaccines
• Subunit Vaccines
• Live Attenuated Virus Vaccines

 Age Group

• Pediatric
• Adult

 End User

• Hospitals and Clinics
• Research Organizations and Academic Institutes
• Others

 Dosage Form

• Nasal Spray
• Intramuscular Injection
• Intradermal Shot

Flu Vaccines Market Regional Analysis/Insights

The flu vaccines market is analysed and market size insights and trends are provided by country, influenza type, manufacturing technology, vaccine type, age group, dosage form and end user as referenced above.

The countries covered in the flu vaccines market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the flu vaccines market due to the growing number of geriatric population along with adoption of innovative medical technology.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the demand for efficient vaccinations is likely to increase.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Flu Vaccines Market Share Analysis

The flu vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to flu vaccines market.

Some of the major players operating in the flu vaccines market are:

• AstraZeneca (U.K.)
• BioDiem (Canada)
• Novasep (France)
• MerckKGaA (Germany)
• Charles River Laboratories (U.K.)
• uniQure N.V. (Netherlands)
• Waisman Biomanufacturing (EUA)
• Creative-Biogene (EUA)
• Aldevron (EUA)
• Oxford Biomédica (Reino Unido)
• Thermo Fisher Scientific Inc (EUA)
• Fujifilm Corporation (Japão)
• Spark Therapeutics Inc.
• (EUA)
• Boehringer Ingelheim International GmbH. (Alemanha)
• Brammer Bio (EUA)
• (EUA)

SKU-55035